Mouse TROP-2 Antibody

Detection of TROP‑2 in mIMCD-3 Mouse Cell Line by Flow Cytometry. mIMCD-3 mouse epithelial cell line was stained with Goat Anti-Mouse TROP-2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1122, filled histogram) or isotype control antibody (Catalog # AB-108-C, open histogram), followed by Allophycocyanin-conjugated Anti-Goat IgG Secondary Antibody (Catalog # F0108).

TROP‑2 in XB2 Mouse Cell Line. TROP-2 was detected in immersion fixed XB2 mouse teratoma keratinocyte cell line using Goat Anti-Mouse TROP-2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1122) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (yellow; Catalog # NL001) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

TROP‑2 in Mouse Skin. TROP-2 was detected in immersion fixed paraffin-embedded sections of mouse skin using Goat Anti-Mouse TROP-2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1122) at 3 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Goat IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC004). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cell membranes in keratinocytes. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Detection of Mouse TROP-2 by Immunohistochemistry Gene expression analysis of Pten mutant prostates.(A) i) Heatmap demonstrating that control samples (C1-C5) show similar expression patterns to each other, as do mutant samples (M1-M5). ii) Genes chosen for validation are indicated in heatmap derived from the average of control and mutant samples. Red indicates genes that are upregulated in mutants (116 genes), relative to controls, and green indicates genes that are downregulated in the mutants relative to controls (91 genes). (B) Quantitative RTPCR validation of indicated androgen-dependent genes differentially expressed in mutants and controls (Clu p = 0.001, Trop2 p = 0.002, Nkx3.1 p = 0.02, and Pbsn p = 0.003). mRNA accumulation was normalized to GAPDH. (C) Differential antibody staining of CLU, TROP2, and PBSN at P10 validated microarray results. (D) Whole mount in situ hybridization of Nkx3.1 shows a decrease in expression in P10 mutant prostates. The anterior prostate (AP), dorsal lateral prostate (DL) and urethra (UR) are indicated. Red arrows indicate presence of stain in the controls and absence in the mutant. “*” denotes statistical significance. Image collected and cropped by CiteAb from the following open publication (https://dx.plos.org/10.1371/journal.pone.0129470), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Mouse TROP-2 by Immunohistochemistry-Paraffin Pten deletion does not lead to an accumulation of progenitor cells.Antibody staining on sections of P0 and P7 prostates with antibodies to CLU and TROP2 shows no accumulation of these proteins at earlier stages of development in controls (A, B, C, D). Increased expression of these markers is seen in the mutant (E, F, G, H) relative to controls from P7. Red arrowheads indicate buds. Image collected and cropped by CiteAb from the following open publication (https://dx.plos.org/10.1371/journal.pone.0129470), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Mouse TROP-2 by Immunohistochemistry Gene expression analysis of Pten mutant prostates.(A) i) Heatmap demonstrating that control samples (C1-C5) show similar expression patterns to each other, as do mutant samples (M1-M5). ii) Genes chosen for validation are indicated in heatmap derived from the average of control and mutant samples. Red indicates genes that are upregulated in mutants (116 genes), relative to controls, and green indicates genes that are downregulated in the mutants relative to controls (91 genes). (B) Quantitative RTPCR validation of indicated androgen-dependent genes differentially expressed in mutants and controls (Clu p = 0.001, Trop2 p = 0.002, Nkx3.1 p = 0.02, and Pbsn p = 0.003). mRNA accumulation was normalized to GAPDH. (C) Differential antibody staining of CLU, TROP2, and PBSN at P10 validated microarray results. (D) Whole mount in situ hybridization of Nkx3.1 shows a decrease in expression in P10 mutant prostates. The anterior prostate (AP), dorsal lateral prostate (DL) and urethra (UR) are indicated. Red arrows indicate presence of stain in the controls and absence in the mutant. “*” denotes statistical significance. Image collected and cropped by CiteAb from the following open publication (https://dx.plos.org/10.1371/journal.pone.0129470), licensed under a CC-BY license. Not internally tested by R&D Systems.